Bluejay Diagnostics (BJDX) Free Cash Flow (2020 - 2026)

Bluejay Diagnostics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$1.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$1.6 million, down 35.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.5 million (up 7.17% YoY), and the FY2025 annual result was -$6.2 million, up 23.38% from the prior year.
• Free Cash Flow came in at -$1.6 million for Q1 2026 at Bluejay Diagnostics, down from -$1.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.2 million in Q1 2025 to a low of -$3.3 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$1.9 million (2022), against an average of -$2.0 million.
• Across the five-year window, Free Cash Flow sank 416.24% in 2022 and jumped 49.31% in 2024, its largest moves.
• Bluejay Diagnostics' Free Cash Flow stood at -$3.2 million in 2022, then grew by 9.96% to -$2.9 million in 2023, then soared by 49.31% to -$1.5 million in 2024, then fell by 0.17% to -$1.5 million in 2025, then dropped by 10.54% to -$1.6 million in 2026.
• The last three Free Cash Flow figures came in at -$1.6 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.